Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Protein S deficiency and novel oral anticoagulants: an intriguing case.

Tàssies D, García de Frutos P.

Thromb Res. 2014 Jul;134(1):1-2. doi: 10.1016/j.thromres.2014.03.008. Epub 2014 Mar 6. No abstract available.

PMID:
24642006
2.

PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy.

Wypasek E, Potaczek DP, Alhenc-Gelas M, Undas A.

Thromb Res. 2014 Jul;134(1):199-201. doi: 10.1016/j.thromres.2014.01.023. Epub 2014 Jan 23. No abstract available.

PMID:
24507871
3.

First case of protein S deficiency due to a translocation t(3;21)(q11.2;q22).

Hurtado B, Nadal M, Margarit E, Sánchez A, Abasolo N, García N, Doménech P, Sala N.

Thromb Haemost. 2009 May;101(5):977-9. No abstract available.

PMID:
19404554
4.

Oral rivaroxaban for symptomatic venous thromboembolism.

Landman GW, Gans RO.

N Engl J Med. 2011 Mar 24;364(12):1178; author reply 1178. doi: 10.1056/NEJMc1100734#SA1. No abstract available.

PMID:
21428778
5.

Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510.

Nunnelee JD.

J Vasc Nurs. 2011 Jun;29(2):89. doi: 10.1016/j.jvn.2011.03.002. No abstract available.

PMID:
21558032
6.

New oral anticoagulants.

Sun D, Lazo-Langner A.

CMAJ. 2013 Mar 5;185(4):E212. doi: 10.1503/cmaj.120078. Epub 2012 Nov 12. No abstract available.

7.

Normal prothrombin time in the presence of therapeutic levels of rivaroxaban.

van Veen JJ, Smith J, Kitchen S, Makris M.

Br J Haematol. 2013 Mar;160(6):859-61. doi: 10.1111/bjh.12173. Epub 2012 Dec 29. No abstract available.

PMID:
23278675
8.

More effective, simpler-to-use clot-buster is on the way. Clot-prevention drug could save lives after joint replacement.

[No authors listed]

Duke Med Health News. 2008 Oct;14(10):6. No abstract available.

PMID:
18927993
9.

Compound heterozygous mutations in the PROS1 gene responsible for quantitative and qualitative protein S deficiency.

Yamanouchi J, Hato T, Tamura T, Fujiwara H, Yakushijin Y, Yasukawa M.

Int J Hematol. 2009 Nov;90(4):537-539. doi: 10.1007/s12185-009-0430-2. Epub 2009 Oct 14. No abstract available.

PMID:
19826897
10.

Rivaroxaban for the treatment of pulmonary embolism.

Vanassche T, Verhamme P.

Adv Ther. 2013 Jun;30(6):589-606. doi: 10.1007/s12325-013-0041-4. Epub 2013 Jun 27. Review.

11.

Inherited protein S deficiency as a result of a large duplication mutation of the PROS1 gene detected by multiplex ligation-dependent probe amplification.

Choung HS, Kim HJ, Gwak GY, Kim SH, Kim DK.

J Thromb Haemost. 2008 Aug;6(8):1430-2. doi: 10.1111/j.1538-7836.2008.03026.x. Epub 2008 May 17. No abstract available.

12.

More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban--early experience from King's College Hospital.

Patel JP, Roberts LN, Chitongo PB, Patel RK, Arya R.

Br J Haematol. 2013 Sep;162(5):717-8. doi: 10.1111/bjh.12423. Epub 2013 Jun 15. No abstract available.

PMID:
23772869
13.

Heerlen polymorphism associated with type III protein S deficiency and factor V Leiden mutation in a Polish patient with deep vein thrombosis.

Wypasek E, Potaczek DP, Alhenc-Gelas M, Undas A.

Blood Coagul Fibrinolysis. 2014 Jan;25(1):84-5. doi: 10.1097/MBC.0b013e328365032c.

PMID:
24365770
14.

[Application of rivaroxabane in patients with proteins C and S deficiency].

Poliantsev AA, Frolov DV, Linchenko DV, Shchelokova IuV.

Khirurgiia (Mosk). 2014;(9):68-71. Russian. No abstract available.

PMID:
25327750
15.

Venous gangrene and intravascular coagulation and fibrinolysis in a patient treated with rivaroxaban.

Rosenbaum AN, Yu RC, Rooke TW, Heit JA.

Am J Med. 2014 Jun;127(6):e7-8. doi: 10.1016/j.amjmed.2014.02.014. Epub 2014 Feb 22. No abstract available.

PMID:
24569023
16.

[Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy].

Einecke D.

MMW Fortschr Med. 2012 Apr 19;154(7):24. German. No abstract available.

PMID:
22558862
17.
18.

A novel nonsense mutation Tyr301* of PROS1 causing protein S deficiency.

Jang MA, Kim SH, Kim DK, Kim HJ.

Blood Coagul Fibrinolysis. 2015 Mar;26(2):223-4. doi: 10.1097/MBC.0000000000000217.

PMID:
25255242
19.

[Oral Rivaroxaban (Xarelto)].

Peeters S, Warnez M.

J Pharm Belg. 2013 Mar;(1):37-40. Review. French. No abstract available.

PMID:
23638611
20.

Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.

Sattari M, Lowenthal DT.

Am J Ther. 2011 Jul;18(4):332-8. doi: 10.1097/MJT.0b013e3181da0773. Review.

PMID:
20535013

Supplemental Content

Support Center